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Abstract: 
 
Patients who are 65 years and older make up nearly half of intensive care unit (ICU) admissions 
and approximately 60% of the ICU hospital days in the United States.1 Cardiovascular (CV) 
conditions are commonly the first or second diagnosis on admission to the ICU. Furthermore, 
even if an elderly patient is not admitted for a CV condition, the physiologic stress of any acute 
illness challenges the heart, often producing structural or functional compromise. For example, 
acute ischemia or dysrhythmias may be the primary condition or a consequence of an initial 
physiologic insult. 
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Article: 
 
Introduction 
 
Patients who are 65 years and older make up nearly half of intensive care unit (ICU) admissions 
and approximately 60% of the ICU hospital days in the United States.1 Cardiovascular (CV) 
conditions are commonly the first or second diagnosis on admission to the ICU. Furthermore, 
even if an elderly patient is not admitted for a CV condition, the physiologic stress of any acute 
illness challenges the heart, often producing structural or functional compromise. For example, 
acute ischemia or dysrhythmias may be the primary condition or a consequence of an initial 
physiologic insult. 
 
Critically ill elders are a physiologically diverse group. Their heterogeneity sometimes makes it 
difficult to separate physiologic aging from the pathology of disease.2 Moreover, as individuals 
age, comorbid conditions become more prevalent, making diagnosis and treatment of acute 
illnesses more challenging. In addition, medications used to treat underlying conditions further 
predispose elders to physiologic compromise during an acute illness. 
 
The most common CV conditions that nurses encounter when caring for critically ill elders 
include hypertension (HTN), acute coronary syndromes (ACS), heart failure (HF), conduction 
disorders (eg, atrial fibrillation [AF]), and valvular heart disease. This article focuses primarily 
on the first 3 conditions because they have the highest prevalence in the elderly population. In all 
the conditions, however, there are common threads among elderly patients hospitalized in the 
ICU. First, cognitive decline among some elderly patients makes history taking challenging for 
health care providers, regardless of the presenting condition. Second, because symptoms in 
elders are often subtle, it is frequently difficult to tease out new symptoms from symptoms 
related to an acute exacerbation of a chronic CV condition. In addition, some elders have 
underlying conditions that have not been formally diagnosed or treated in the past, making 
interpretation of diagnostic testing difficult because baseline comparisons are unavailable. 
Finally, as individuals age, they experience decline in kidney and liver function, which 
influences laboratory findings (eg, cardiac biomarkers, such as troponin or brain natriuretic 
peptide values) and the way that individuals are treated medically. 
 
Physiologic changes to the heart 
 
Age-related changes to the CV system affect both the physiologic functioning of the 
heart and the way elderly individuals respond to medical therapy to treat CV conditions. These 
changes occur progressively over time; however, some individuals decline more rapidly than 
others.1 Some of the physiologic changes are related to chronologic age itself, whereas others are 
related to lifestyle. As a result of these physiologic changes, over time, there are decreases in 
maximal heart rate (HR), ejection fraction (EF), and cardiac output (CO). Table 1 gives a 
summary of age-related physiologic changes to the heart.1–4 
 
TABLE 1 CAN BE FOUND AT THE END OF THE ARTICLE 
 
Hypertension 
 
Burden of the condition 
 
Approximately two-thirds of adults age 65 and older have HTN, and this figure increases to 
nearly 80% among those 75 and older. This is primarily because as individuals age, systolic 
blood pressure (SBP) tends to steadily increase, regardless of whether the individuals are being 
treated for HTN.5 Diastolic blood pressure (DBP), on the other hand, peaks in the fourth or fifth 
decade of life, then steadily decreases over time.5 Therefore, when considering baseline blood 
pressure (BP) readings outside the hospital, it is common for most elders to have isolated systolic 
HTN.4 
 
Unfortunately, only about three-fourths (71%) of adults age 65 and older are aware that they 
have the HTN.6 Furthermore, among those diagnosed with HTN, only about 69% receive 
treatment and fewer than half (48.8%) reach BP treatment goals.6 Control rates are worse for 
elders age 80 and older, with only 38% of men and 23% of women meeting BP treatment 
goals.6 For these reasons, elders are more likely to have complications related to uncontrolled 
HTN. 
 
Hypertension crisis 
 
One of the complications of uncontrolled HTN is an HTN crisis, which occurs in approximately 
1% to 2% of those with HTN.7 Although this percentage is low compared with the high 
prevalence of HTN in elders, the consequences of having an HTN crisis can be devastating. 
Formerly referred to as malignant HTN or accelerated HTN, currently an HTN crisis may be 
classified as HTN urgency or HTN emergency. Distinguishing between an urgent and an 
emergent HTN crisis is not based solely on BP measurement; instead, it is based on whether end-
organ damage exists.7 Specifically, HTN urgency is defined as an abrupt rise in BP without signs 
of end-organ damage. HTN urgency typically occurs when the DBP is 120 mm Hg or greater. 
Patients diagnosed with HTN urgency need to have their BP controlled within 24 hours to 
several days.7 This group of patients may be treated with oral medications on an outpatient basis. 
 
In contrast, an HTN emergency is defined as an abrupt rise in BP that is associated with CV, 
kidney, or central nervous system end-organ damage.7 Individuals diagnosed with an HTN 
emergency require immediate medical attention because of the life-threatening nature of the 
situation and the increased likelihood of end-organ damage (encephalopathy, acute aortic 
dissection, stroke, ACS, acute pulmonary edema, and kidney failure). These patients are 
typically admitted to the ICU for treatment. Thus, the remainder of this section related to HTN 
crisis, focuses on this group of critically ill elders. 
 
Cause of an HTN crisis 
 
Most patients who have an HTN crisis have uncontrolled HTN as their baseline, but many of 
them have never been formally diagnosed with high BP. Other common risk factors include 
kidney disease (renal artery stenosis, glomerulonephritis, or renal cell carcinoma), endocrine 
disorders (diabetes, Cushing syndrome, primary hyperaldosterism, pheochromocytoma), drugs 
(cocaine, sympathomimetics, abrupt withdrawal of some antihypertensive agents), central 
nervous system disorders (head or spinal cord injury, cerebral infarction or hemorrhage, brain 
tumor), and postoperative pain or complications.7However, the mechanisms that trigger an HTN 
crisis on a particular day are not completely understood. Normally at baseline, even with 
fluctuations in BP throughout the day, an individual’s compensatory mechanisms allow for a 
relatively constant perfusion to vital organs.8 Yet, in the case of an HTN crisis, an initial insult 
serves as the stimulus to abruptly increase BP.7 The arterioles sense this sharp increase in BP and 
signal to the vascular endothelium to release nitric oxide (a vasodilator) as a means to 
compensate.7 In addition, the arterial smooth muscle contracts to reduce the rise in BP. Over 
time, however, the endothelium is unable to release enough nitric oxide to buffer the severe and 
sudden rise in BP. Compensatory mechanisms fail as a result of prolonged arterial smooth 
muscle contraction, a gradual increase in endothelial dysfunction, and an inability to release 
more nitric oxide, resulting in rapid and progressive decompensation of vital organ 
function.7,8One of the most serious consequences of a HTN emergency is cerebral edema and 
microhemorrhages that result from the elevated pressure. These are due to the inability of the 
brain’s autoregulation to tolerate sudden severe changes in BP (increases or decreases). Thus, 
neurologic deficits occur due to the vasodilation, edema, and increased intracranial pressure 
(ICP). Interestingly, some patients with a long history of HTN are able to tolerate the acute 
increase in mean arterial pressure (MAP) without increasing cerebral perfusion, thereby avoiding 
an increase in ICP. 
 
Obtaining accurate BP readings in elders 
 
It is imperative that nurses measure BP correctly for all patients in the ICU, especially those with 
suspected HTN emergencies. Nurses need to consider 3 things that affect BP readings: (1) 
physiologic differences in elders that may influence manual or noninvasive readings; (2) 
differences in values obtained by noninvasive and invasive methods; and (3) differences between 
SBP versus MAP readings. Nurses should know that it is common for elderly patients to have an 
ausculatory gap, a period during manual BP measurement when the true SBP fades away, then 
recurs at a lower pressure point.4 This is usually associated with vascular disease caused by long-
standing HTN. Thus, when taking manual BP readings, the cuff needs to be inflated high enough 
to capture the true starting point of the SBP, or otherwise the reading may be falsely low. 
Additionally, some elders have pseudohypertension, a falsely elevated SBP resulting from 
markedly sclerotic arteries that will not collapse as the BP cuff is inflated.4 To assess for this 
abnormality, the nurse should palpate the pulse distal to the location of the BP cuff during 
measurement.4 If the pulse remains palpable, despite having the BP cuff inflated above the SBP, 
the nurse should suspect pseudohypertension. In this case, only direct measurement of BP (eg, 
via an arterial line) will reveal an accurate BP.4 
 
Nurses also need to be aware of the differences between noninvasive blood pressure (NIBP) 
readings and invasive arterial pressure readings, which are made when patients experience 
extremes in BP.9 Specifically, when a patient is hypotensive, the NIBP runs higher than invasive 
BP for SBP readings. When a patient is hypertensive, the NIBP runs lower than with the invasive 
method. Thus, during hypotensive or hypertensive episodes, the NIBP may not capture the full 
extent of deviation. Furthermore, NIBP systolic readings are not as sensitive as intra-arterial 
readings in assessing a patient’s risk of developing acute kidney injury. Lehman and 
colleagues9 advise that if NIBP readings are used, nurses should avoid hypoperfusion in those at 
risk for acute kidney injury; parameters for the lower limit of the SBP should be higher than the 
usual threshold of lower than 90 mm Hg. These findings, however, do not mean that an invasive 
method should be used to obtain BP in every patient in the ICU, just that these differences should 
be considered. 
 
Regardless of which method is used to obtain the BP, the MAP is a more consistent metric than 
SBP to use to guide therapy in the ICU.9 The MAP is the “true driving pressure” for peripheral 
blood flow.9 Unfortunately, nursing practice has been slow to adopt use of MAP, especially 
when NIBP methods are used. Generally, the upper threshold for MAP is between 60 and 65 mm 
Hg, but goals may be individualized by the medical team based on comorbid conditions.9 
 
Evaluation of patients with HTN emergencies 
 
In addition to obtaining accurate BP readings, it is vital to conduct a thorough history and 
physical examination as part of the admission assessment of a patient with an HTN emergency. 
If the patient is unable to provide the information, the nurse should ask whether someone close to 
the patient (a family member, caregiver, partner) is available to provide the information. 
Assessment of medical history should include history of antihypertensive treatment, including 
adherence to the regimen, illicit drug use, symptoms of other CV conditions (eg, HF, angina, 
aortic dissection), symptoms of neurologic deficits (eg, nausea, vomiting, headache, mental 
status changes, weakness, blurred vision), and symptoms of kidney disease (eg, hematuria or 
oliguria). In addition, ascertaining whether the patient has a history of thyroid disease, Cushing 
syndrome, systemic lupus, or systemic sclerosis is helpful in determining potential causes. 
 
A focused physical examination should include a CV and neurologic assessment. As part of the 
CV examination, BP should be measured in both arms, to check for differences. In addition, the 
nurse should assess for absent or delayed peripheral pulses (to rule out dissection), auscultate 
heart and lung sounds (extra heart sounds, such as an S3, or adventitious lung sounds, such as 
rales, to rule out pulmonary edema), and check the mental status of the patient as part of 
neurologic checks (to rule out cerebral hypoperfusion). A fundoscopic examination should also 
be done by the medical team to assess for soft exudates, hemorrhages, and papilledema. 
Diagnostic tests should include a 12-lead electrocardiogram (ECG), a chest radiograph, a brain 
computed tomography scan, and laboratory assessments, including urinalysis, electrolytes with a 
serum creatinine, complete blood count, cardiac enzymes (especially if acute ischemia is 
suspected), and BNP, especially if acute HF is suspected. 
 
Treatment of HTN crises 
 
Treatment for an HTN crisis is challenging because there is a lack of evidence-based guidelines 
for clinical care, especially for elders. However, there are general treatment recommendations for 
patients with an HTN emergency. The first order of treatment, in addition to determining 
whether the HTN crisis is an emergent crisis or an urgent crisis, is to address and control any 
acute precipitating causes (eg, anxiety, pain, hypoxia, hypercapnia, or hypoglycemia).10 The 
patient also should be admitted to the ICU and given parenteral medications to reverse end-organ 
damage related to an HTN emergency.10During this time, intra-arterial BP monitoring is required 
when using certain intravenous (IV) medications, to obtain the most accurate readings.10 
 
When treating a patient with an HTN emergency, a critical point to remember is that the BP does 
not need to be corrected urgently. Too rapid reduction of BP can result in serious ischemia, 
cortical blindness, hemiplegia, acute myocardial infarction (MI), and/or acute kidney failure, 
especially with elders who have long-standing HTN.10 Instead, allowing a patient’s 
autoregulation to adapt to the clinical situation by decreasing the BP more slowly results in better 
outcomes. The treatment goal is to restore normal perfusion pressure to the vital organs, not to 
reach the “normal” target BP goal established for outpatients.8 
 
Initially BP measurements should be assessed every 5 to 10 minutes (after the first measurement 
is obtained).10 A good rule of thumb is that the MAP should be lowered over a period of 2 to 
6 hours after the time of presentation, but not by more than 25% of the initial value at 
presentation.7 This should translate to about a 10% decrease in the first hour, with another 15% 
decrease over the next 2 to 3 hours.7 To accomplish this, medications need to be effective within 
the first hour after diagnosis.10 An exception to this rule is patients experiencing an aortic 
dissection. In this case, the target SBP should be 120 mm Hg within the first 20 minutes; then an 
SBP between 100 and 120 mm Hg should be maintained.7 To do so, medications need to be 
effective within the first 10 minutes after diagnosis.10 In the case of an aortic dissection, because 
SBP is being lowered more rapidly than in other HTN emergencies, the nurse should monitor the 
patient closely for signs and symptoms of cerebral hypoperfusion (eg, nausea, headache, 
confusion, psychomotor slowing, or agitation). Table 2 provides a summary of steps in the 
nursing care of patients with HTN emergencies, including specific BP goals for various clinical 
situations. 
 
TABLE 2 CAN BE FOUND AT THE END OF THE ARTICLE 
 
Treatment for HTN emergencies 
 
In addition to avoiding an abrupt reduction in BP, nurses treating elders with HTN emergencies 
should start with lower doses of medications, assess for side effects frequently, and be aware that 
many elders are admitted with a fluid volume deficit. Volume depletion on arrival at the ICU is 
likely to be due to pressure-induced natriuresis, which may be the patient’s baseline status if the 
patient is dehydrated, especially in the summer months.4,11 Thus, unless there are clear signs of 
fluid overload, administration of loop diuretics should be avoided in elders presenting with an 
HTN emergency. In fact, in some cases of volume depletion, patients may need volume 
expansion. 
 
There are different routes of administration for medications to treat HTN emergencies. The IV 
route is most common because of the relatively short half-life, making these agents easier to 
titrate, more flexible to use, more likely to have a rapid onset of action, and more likely to have a 
shorter duration.9 It is important to note that sublingual administration of phentolamine, 
clonidine, diazoxide, or nifedipine is contraindicated due to the likelihood of severe hypotension 
with use.9 
 
Most IV agents require intra-arterial BP monitoring and continuous ECG monitoring during the 
acute phase of an HTN emergency to assess for changes in perfusion status.9 Some agents are 
preferred over others, depending on the patient’s condition(s) at the time of presentation (eg, 
cerebral edema, aortic dissection, acute ischemic or hemorrhagic stroke, ACS, acute HF, or acute 
kidney failure, or if a patient is in the acute postoperative setting). Once the BP is stabilized with 
IV medications, a conversion to oral therapy typically occurs within 6 to 12 hours.6 
Table 3 provides information on the most common medications used to treat HTN emergencies. 
 
TABLE 3 CAN BE FOUND AT THE END OF THE ARTICLE 
 
Heart Failure 
 
Burden of the condition 
 
As with HTN, the prevalence of HF increases with age; about half of the adults with HF in the 
US are at least age 75.12,13 It is generally considered a condition of elders.14 HF is the leading 
cause of hospitalization for those age 65 and older.6,14,15 At baseline, elders with HF are more 
likely to be women, to have preserved systolic function (ie, normal EF), and to have isolated 
systolic HTN as the precipitating cause of HF.12 Younger adults with HF are more likely to be 
men, have systolic dysfunction, and to have an ischemic etiology.12However, of those elders who 
are admitted with HF, the percentage with systolic dysfunction is higher than among those in the 
community.12,13 
 
Systolic HTN is the greatest risk factor for the development of HF, especially among 
women.12,13 In addition to increased age and systolic HTN, risk factors for HF in the elderly 
include having coronary heart disease (CHD), AF, a widened pulse pressure, diabetes, chronic 
lung disease, kidney dysfunction, left ventricular hypertrophy (LVH), and obesity. Age-related 
changes to the CV system (eg, increased arterial and ventricular stiffness, impaired beta-
adrenergic responsiveness), combined with age-related changes to the kidneys and lungs, place 
elders at risk for the development of HF.12,13 These combined age-related effects and comorbid 
conditions also influence the ability of elders to compensate during an exacerbation of HF and 
their response to treatment during exacerbations. 
 
Acute decompensation of HF 
 
Acute decompensated heart failure (ADHF) is a clinical classification of rapidly worsening HF 
and is primarily diagnosed by a patient’s signs and symptoms.15,16 Approximately 80% of 
individuals with ADHF have chronic HF that acutely decompensates, known as “acute on 
chronic HF.”16,17 These patients typically present with a history of progressive, worsening 
chronic HF, usually with evidence of either systemic or pulmonary congestion.15,16 The 
remaining 20% of patients with ADHF have new-onset HF.16 During acute episodes, the renin-
angiotensin-aldosterone system (RAAS) is activated, causing an increase in sodium and water 
retention by the kidneys, an increase in circulating blood volume, and an increase in venous 
pressure.12,15 Fluid accumulates in the lung’s interstitial and alveolar spaces, resulting in acutely 
elevated cardiac filling pressures.15,16 These high-risk patients require immediate medical 
attention, are usually hospitalized in the ICU, and receive acute pharmacologic therapy. 
 
Precipitating factors for ADHF 
 
Decompensation is typically caused by one or more precipitants; rarely does ADHF occur 
because of a sudden decline in the structure or function of the heart.15,16 Instead, decompensation 
is usually associated with worsening comorbid conditions (eg, worsening kidney function), a 
gradual decline in myocardial function, and/or persistent neurohormonal activation caused by the 
chronic underlying cardiac condition.15,16 Reasons for decompensation may differ based on the 
type of HF a patient has. For example, the primary reason for decompensation in patients with 
reduced EF is impaired contractility (increased end-systolic volume), often due to 
ischemia.12,13 Elderly patients who have increased systemic vascular resistance, higher 
norepinephrine levels, and impaired kidney function are more likely to go into acute HF, 
especially during times of ischemia.12 
 
In contrast, the primary reason for decompensation in patients with preserved EF is inability to 
increase left ventricular (LV) stroke volume due to the presence of increased vascular stiffness, 
despite increased LV filling pressures.12 This group experiences impaired relaxation of the LV, 
and thus has difficulty receiving blood into the ventricle. In the past, it was thought that transient 
systolic dysfunction, acute ischemia, or mitral regurgitation played the primary role in acute 
pulmonary edema in these patients. However, a more current view of the pathogenesis of acute 
pulmonary edema is that it is a consequence of markedly elevated SBP.12,18 There are several 
pathophysiological mechanisms for decompensation in patients with preserved EF (abnormalities 
in ventricular diastole, vascular stiffness, circulatory volume overload, and atrial dysfunction) all 
more likely with advanced age.12,18 Increases in LV mass and LV volume from long-standing 
HTN, diabetes, or obesity further compromise the patient.12 Also, because LV relaxation is 
sensitive to changes in afterload and HR, patients can more easily decompensate during episodes 
of HTN or tachycardia.12 Box 1 provides a list of possible precipitants of ADHF. 
 
Box 1. Precipitants for acute decompensated heart failure 
• Ischemia (ACS) 
• Worsening or uncontrolled HTN 
• Dysrhythmias (eg, AF or atrial flutter) 
• Valvular abnormalities (eg, mitral regurgitation) 
• Comorbid conditions (eg, diabetes, thyroid disease, pulmonary disease, or 
new/worsening kidney disease) 
• Infections (eg, chest infections, pneumonia, myocarditis, pericarditis, or endocarditis) 
• Hematologic disorders (eg, severe anemia or bone marrow suppression) 
• Nonadherence with medications or sodium/fluid restrictions (may be due to financial 
or knowledge factors) 
• Cardiotoxic agents (alcohol or illicit drug use) 
• Iatrogenic factors (agents that cause sodium or water retention; medications that are 
negative inotropes; sympathomimetic use [eg, pseudoepinephrine, ephedra, or 
amphetamines]) 
Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; HTN, hypertension. 
 
Signs and symptoms of ADHF 
 
Assessing symptoms of HF is challenging in elderly patients because they are more likely to 
attribute their symptoms to getting older, being deconditioned, or being obese. They are also 
unlikely to report exertional symptoms if they lead a sedentary life.12 As with many CV 
conditions, their symptoms are also more likely to be atypical (eg, somnolence or malaise, 
weakness or confusion, irritability, anorexia, general abdominal complaints, sleep disturbance, or 
decreased activity).12 However, nurses should be knowledgeable about the classic presentations 
of ADHF. 
 
The most common presentation of ADHF includes pulmonary and systemic congestion without a 
decline in cardiac output.15 In fact, many patients (30%–50%) who are evaluated in the 
emergency department or hospitalized for ADHF have systemic HTN (SBP>140 mm Hg) at the 
time of evaluation, not hypotension.15 Cardinal signs and symptoms of ADHF include shortness 
of breath, congestion, and fatigue.12,14,15 Congestion may occur as pulmonary congestion or as 
systemic congestion. Thus, nurses should keep in mind that pulmonary congestion may be 
present, even in the absence of rales/crackles or evidence of fluid on the chest 
radiograph.14,15 Although not the majority, some patients present with low output (inadequate 
tissue perfusion). Symptoms of inadequate perfusion may be more subtle than those of 
congestion, especially in elders.12 Therefore, nurses should be able to recognize the signs and 
symptoms of low output promptly, because cardiogenic shock may be imminent in patients who 
have low cardiac output.12 Table 4 lists the signs/symptoms of ADHF. 
 
TABLE 4 CAN BE FOUND AT THE END OF THE ARTICLE 
 
Diagnosis of ADHF 
 
The diagnosis of ADHF is primarily based on the patient’s clinical signs and 
symptoms.14,15 However, there are some tests that are useful in confirming the diagnosis, 
assessing the severity of disease, and evaluating the results of therapy. Two sub-types of 
natriuretic peptides, B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic 
peptide (NT-proBNP), may be ordered to increase certainty about the diagnosis.14,15These 
naturally occurring hormones, secreted from the atria and ventricles as a result of cardiac 
dilation, have been found to be highly predictive in diagnosing patients with HF, regardless of 
whether they have a normal EF or low EF.14,15 Both types of hormones increase with age, 
particularly in women, in obese individuals, and in those with kidney impairment.15 Assay 
specificity is lower for elders, especially older women with preserved LV function (age 70–
105 years), than for younger patients (18–69 years) with HF.15 NT-proBNP has a longer half-life 
and in general runs about 4 times higher than BNP.15 Despite these limitations in specificity, 
there are cut points for diagnosis. A BNP level greater than 500 pg/mL is considered diagnostic 
of ADHF.15 The cut point for a positive diagnosis of ADHF by NT-proBNP testing is based on 
age: higher than 450 pg/mL for patients younger than 50, higher than 900 pg/mL for those age 50 
to 75 years, and higher than 1800 pg/mL for those older than 74.15 Although natriuretic peptides 
may be helpful in improving diagnostic certainty, the usefulness of serial measurement of these 
tests to reduce hospitalization or mortality is not well established.14 Furthermore, current 
recommendations for the treatment of HF advise that natriuretic peptides may be useful in the 
outpatient setting to optimize medical therapy.14 However, more research is needed before 
recommending widespread use. 
 
Echocardiography is considered the gold standard noninvasive test for diagnosing and 
monitoring HF.12,14,15 An echocardiogram provides information about both cardiac structure and 
function, including estimates of LVEF, wall motion abnormalities, and the integrity of the heart 
valves, all of which are helpful in sorting out the etiology of the HF. However, standard 
echocardiography is unable to distinguish diastolic dysfunction related to “normal” aging from 
HF.12,14,15 Thus, it is best to combine standard echocardiography with Doppler imaging to ensure 
accurate assessment diastolic function. 
 
Other diagnostic tests typically done for patients admitted with ADHF include chest radiograph 
(to rule out cardiac enlargement, pulmonary congestion, pleural effusion, pneumothorax, and/or 
the placement of cardiac devices), 12-lead ECG (to assess heart rate and rhythm or the presence 
of LVH or acute ischemia), and standard laboratory studies (serum electrolytes, including 
calcium, magnesium, and phosphorus, complete blood count, serum albumin, uric acid, liver 
function tests, and thyroid function studies).14,15 
 
Treatment of ADHF 
 
Primary treatment goals for patients admitted with ADHF include improving symptoms 
(especially symptoms of congestion and low output), restoring oxygenation, and optimizing 
volume status.12,14,15 In addition, hospitalization provides an opportunity for the medical team to 
reevaluate the ongoing treatment regimen to ensure that the patient is receiving guideline-
directed medical therapy for optimal short-term and long-term outcomes. Box 2 lists the 
treatment goals for patients hospitalized with ADHF. 
 
Box 2. Treatment goals for acute decompensated heart failure 
Data from Refs.12,14–16 
• Improve symptoms, especially those related to congestion and low output 
• Restore oxygenation 
• Optimize volume status 
• Identify the etiology of the HF 
• Identify and correct precipitating factors 
• Optimize chronic therapy 
• Minimize side effects of treatment regimen 
• Identify which patients may benefit from revascularization and/or device therapy 
• Identify which patients are candidates for anticoagulation therapy (high risk for 
thromboembolism) 
• Educate patients and families concerning treatment regimen and self-assessment of 
HF 
• Refer to a disease management program if available 
Abbreviation: HF, heart failure. 
 
Many clinicians use a classification system to assign a clinical profile to patients with ADHF to 
guide pharmacologic therapy with IV diuretics, inotropes, and/or vasodilators. Classification 
systems differentiate clinical profiles based on the adequacy of tissue perfusion (“warm” vs 
“cold”) and the degree of congestion (“wet” vs “dry”).14–16 The most frequent presentation of 
ADHF is the “warm and wet” clinical profile.15,16 Patients with this profile should generally be 
treated with IV loop diuretics or an increased dose or increased frequency of oral diuretics, 
because of their congestion.14–16 In addition to diuretics, vasodilators (such as nitroglycerin, 
sodium nitroprusside, or nesiritide) may be used for patients with this profile, as their BP 
generally permits use.14–16 Patients with a second type of clinical profile, those who are “cold and 
wet,” are also treated with IV loop diuretics because the etiology of hypoperfusion is likely to be 
congestion. However, diuretics may be minimally effective if perfusion to the kidneys is affected 
by the low output.14–16 Regardless of the presence or absence of congestion, inotropes (eg, 
dopamine, dobutamine, or milrinone) are used for all patients classified as “cold” to assist with 
circulation.14–16,19 The third profile, “warm and dry,” is actually the “target” profile that is 
desired after treatment. However, if patients who present with ADHF have adequate perfusion 
and are without congestion, treatment should focus on searching for other causes of their HF 
(such as ACS, pulmonary embolus, infection, anemia, hypothyroidism, or depression).14–16 In 
this case, they should not receive IV diuretics (to avoid hypotension). The final profile for 
hospitalized patients with ADHF is the “cold and dry” clinical profile, which is least prevalent. 
Inotropes are the treatment of choice because of the hypoperfusion (“the coldness”).14–
16,19 Diuretics and vasodilators are not given because of the potential for marked hypotension or 
irreversible organ damage.14–16 Table 5 provides a summary of the clinical profiles and general 
treatment recommendations. 
 
TABLE 5 CAN BE FOUND AT THE END OF THE ARTICLE 
 
Regardless of which clinical profile the patient has, there are general principles that nurses 
should consider when administering IV diuretics, vasodilators, and inotropes to patients with 
ADHF. Generally considered first-line agents, IV loop diuretics should be given to all patients 
with evidence of fluid overload.12,14–16 Administration by the IV route is preferred over the oral 
route because of better effectiveness and a faster clinical response (as rapidly as 15 minutes in 
some patients) with IV diuresis.14–16,19 Symptomatic relief is generally obtained within 1 to 
2 hours, compared with oral maintenance doses, which may take weeks to rid excess fluid.15 If 
the patient has a history of chronic HF and decompensates acutely, the initial dose of IV diuretic 
should equal to or exceed their long-term oral daily dose.14,16 Higher doses may be needed for 
those with kidney disease or those with severe fluid overload to gain symptomatic 
relief.14,15 Current treatment guidelines for ADHF do not specify a preference for intermittent 
bolus injections of IV diuresis versus a continuous infusion.14,15 Advantages of intermittent bolus 
injections include the convenience of administering the medication at a specific time and that 
continuous IV access is not required.16,20 However, some patients do not respond to intermittent 
bolus injections; thus, a continuous infusion of a loop diuretic should be considered.14–
16,20 Advantages to a continuous infusion include a more constant delivery of the agent to the 
kidneys and less chance of causing prerenal azotemia, less chance of causing side effects from 
fluctuations in drug levels, and less chance of developing rebound sodium reabsorption if the 
drug were to drop below the therapeutic range.16,20 Other recommendations for patients who do 
not respond to the initial dose of IV diuresis include increasing the dose of the loop diuretic, 
adding a second type of diuretic (thiazide) to work synergistically with the loop diuretic, 
implementing a sodium and fluid restriction for the patient, and consideration of ultrafiltration, if 
available at the facility.14–16,20 In contrast, for patients who develop worsened kidney function 
after receiving IV diuresis, treatment options include a temporary dose decrease or 
discontinuation of the diuretic, use of vasodilator or inotrope therapy, or short-term hemodialysis 
may be considered for patients who have continued fluid volume overload in the setting of 
worsened kidney function.16 Table 6 gives information on IV diuretics used to treat ADHF. 
 
TABLE 6 CAN BE FOUND AT THE END OF THE ARTICLE 
 
Vasodilators, generally considered second-line agents, are best used for patients who have 
volume overload, yet normal or elevated BP (ideally an SBP of >110 mm Hg).14–16,19 All IV 
vasodilators need to be administered by an infusion pump, and some facilities require invasive 
hemodynamic monitoring when administering some of these agents (such as sodium 
nitroprusside).14–16 Inotropes are typically considered a third-line agent in some patients with 
ADHF because current guidelines deemphasize the use of inotropes as compared with 
vasodilators. However, IV inotropes are a good option for patients who have symptomatic 
hypotension (SBP<90 mm Hg) or borderline SBP who are unable to receive vasodilators safely. 
Inotropes help patients with severe systolic dysfunction, hypotension, or evidence of low cardiac 
output, with or without congestion, to maintain systemic perfusion and preserve end-organ 
performance.14–16,19 Table 6 also provides information on IV vasodilators and IV inotropes used 
to treat ADHF. 
 
Other miscellaneous medications for ADHF 
 
Traditionally, IV morphine has been used to stabilize patients with acute pulmonary edema. 
However, recent studies have shown that morphine given to acutely ill patients with ADHF is 
associated with worse outcomes (longer hospital stay, need for mechanical ventilation, need for 
ICU, and higher overall mortality).15 The mechanism related to this association is unclear. Thus, 
the current guidelines for treatment of ADHF indicate that morphine should be used cautiously, 
especially in those with impaired respiratory drive or altered mental status.15,16 If used at all, 
morphine should be given at low doses (2.5–5.0 mg) and the patient should be monitored for side 
effects (eg, hypotension, bradycardia, advanced heart block, and carbon dioxide retention).15 
 
Digoxin is generally not used in the acute setting of ADHF. However, some patients may be on 
digoxin before hospitalization (eg, those with preexisting HF or AF) and may continue to receive 
the medication throughout their hospital stay. Although digoxin helps decrease symptoms of HF, 
the use of this agent has not been shown to improve survival, especially in the acute setting. The 
use of digoxin in managing patients with ADHF is not addressed in the current treatment 
guidelines.15,16 If digoxin is used, doses are generally lower than previously advised, especially 
in elders or those with kidney dysfunction.12 This is largely due to an analysis of the Digitalis 
Investigation Group (DIG) study, which showed that the maximum benefit of digoxin was 
evident at serum levels of 0.5 to 0.8 ng/mL.12,21 In fact, digoxin levels greater than 1.2 
(previously thought to be “therapeutic”) were associated with increased mortality.12,21 Thus, a 
dosage of 0.125 mg daily is adequate for most elders with normal kidney function; and a lower 
dosage (0.125 mg 1–3 times per week) is appropriate for those with impaired kidney 
function.12,22 
 
Aspirin is also not indicated for ADHF, unless the patient has a known history of CHD or is 
experiencing acute cardiac ischemia. If aspirin is given, the lowest dosage (81 mg daily) should 
be used to minimize the chance of bleeding or interaction with angiotensin-converting enzyme 
(ACE) inhibitors.15,16 
 
Maintenance therapies in the setting of ADHF 
 
Medications given in the acute ICU setting for ADHF are generally given to improve the 
patient’s symptoms and hemodynamics. However, hospitalization also offers an opportunity to 
optimize long-term therapy for patients transitioning from the hospital to the community. Long-
term benefits of maintenance therapies include attenuating (slowing down) the disease process, 
decreasing the chances of rehospitalization, and improving survival. Maintenance therapy 
includes ACE inhibitors (or angiotensin receptor blockers [ARBs], if allergic), beta-adrenergic 
antagonists (beta-blockers), loop diuretics, aldosterone antagonists, and digoxin (for some 
patients with reduced LVEF).12,14,15 However, nurses should be aware that elders are at increased 
risk for side effects from these therapies. For example, because elders have a greater likelihood 
of underlying chronic kidney disease and renal artery stenosis, they are at an increased risk of 
orthostatic hypotension or worsened kidney function when given ACE inhibitors, especially if 
patients take nonsteroidal anti-inflammatory drugs.12 Elders are also at higher risk for kidney 
dysfunction and electrolyte abnormalities with the use of diuretic therapy.12,14 Thus, the lowest 
possible dose of diuretic should be used, while still maintaining euvolemia (normal fluid volume 
status).12 Thus, the in-patient setting may provide an opportunity for close monitoring that would 
otherwise not be available as an outpatient to monitor for these potential side effects (especially 
if patients have borderline or low BP, a low HR, or have borderline electrolyte 
abnormalities). Box 3 provides pearls for starting or up-titrating maintenance therapies for 
patients who have been hospitalized for ADHF. 
 
In rare circumstances, a patient’s baseline therapy may have to be temporarily discontinued when 
they are admitted for ADHF. For example, if the patient with chronic HF is admitted with 
cardiogenic shock, refractory volume overload, or symptomatic bradycardia, then it would be 
appropriate to temporarily discontinue or give half their usual dose of beta-blocker (as opposed 
to complete discontinuation of the medication).15 Also if the patient’s SBP is lower than 80 mm 
Hg, is experiencing symptomatic hypotension, or has a markedly elevated creatinine compared 
with baseline, ACE inhibitor (or ARB) therapy should be reduced or temporarily discontinued 
until kidney function improves.15 Finally, if a patient’s kidney function dramatically worsens or 
their potassium become markedly elevated (>5.5 mEq/L) aldosterone antagonists (spironolactone 
or eplerenone) should be temporarily discontinued until the potassium has normalized or the 
kidney function has returned to baseline.15 
 
Box 3. Pearls for starting or up titrating maintenance therapies 
Data from Lindenfeld J, Albert NM, Boehmer JP. Heart Failure Society of America, executive 
summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 
2010;16(6):e1–194; and Coons JC, McGraw M, Murali S. Pharmacotherapy for acute heart 
failure syndromes. Am J Health Syst Pharm 2011;68:21–35. 
• ACE-inhibitors (or ARBs) can be started (or up-titrated) if the kidney function is 
stable. 
• Doses of ACE inhibitors (or ARBs) can be adjusted more frequently in the in-hospital 
setting, because side effects and laboratory findings can be monitored more closely. 
• Generally, patients should be on target doses of ACE inhibitors (or ARBs) and on a 
low-dose diuretic before starting beta-blocker therapy for chronic HF. 
• For patients who are newly diagnosed with HF, beta-blocker therapy should be 
started at the lowest dose 24 hours before hospital discharge, after the volume status is 
optimized, successful conversion of IV to oral diuretics has occurred, and after all 
vasodilators or inotropes have been weaned off. 
• Patients on chronic beta-blocker therapy who are not yet at target doses may have 
their beta-blocker up-titrated 24 hours before hospital discharge (with the same 
conditions as above). 
• After hospital discharge uptitration of beta-blocker and ACE-inhibitor therapy should 
occur every 2 to 4 weeks during a face-to-face visit to allow for assessment of vital 
signs and fluid volume. 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HF, 
heart failure; IV, intravenous. 
 
 
Acute Coronary Syndrome (ACS) 
 
Elders in the ICU are at an increased risk for acute cardiac ischemia, either from ACS or from 
the physiologic stress to the heart from other acute illnesses. Some patients with ACS have a 
history of stable angina that escalates prior to the event; others have no prior symptoms. 
 
The diagnosis of ACS is an umbrella term that includes patients with unstable angina (UA), non–
ST-Segment-Elevation MI (NSTEMI), or ST-Segment-Elevation MI (STEMI). UA refers to 
acute ischemic symptoms that increase in frequency and severity over time, often occurring at 
rest, either due to an increased demand for myocardial oxygen or a decreased supply (subtotal 
occlusion) of one or more coronary arteries.6 The ischemia is transient and reversible, thus does 
not result in necrosis (death) of the myocardial tissue as with MI.6 In contrast, an MI involves a 
total occlusion of at least one coronary artery, resulting in irreversible necrosis of the tissue that 
is supplied by the infarct-related artery. An STEMI is diagnosed if a symptomatic patient’s 12-
lead ECG has acute ST-segment elevation in 2 or more contiguous leads; whereas, patients who 
have ischemic symptoms without ST-segment elevation on their 12-lead ECG, yet rule in for an 
MI by cardiac enzymes (eg, creatine kinase MB [CK-MB] or troponin levels), are classified as 
NSTE MI. 
 
Burden of the condition in elders 
 
As individuals age, they are at greater risk for having an ACS event.23,24 The median age for 
first-time MI in the United States is approximately 65 for men and 74 for women.5Furthermore, 
35% of all MIs occur in persons 75 and older; 11% occurring in persons 85 and 
older.23 Although the absolute numbers of patients with STEMI increases with age, elders are 
more likely to have an NSTE MI.24 This is because elders are more likely to have complex 
calcified CHD, prior revascularization, and ACS due to other (secondary) conditions (eg, 
pneumonia, gastrointestinal bleeding, or sepsis).23,24 
 
Advanced age is also an independent predictor for complications following an ACS event, 
including a higher risk of HF, bleeding, mechanical complications, and death.24 In addition, ACS 
accounts for 35% of all deaths in adults 65 years and older, which increases sharply after the age 
of 75.24 However, evidence-based treatment has been shown to improve mortality and morbidity 
in elderly patients with ACS, although not equal the outcomes of younger patients.23,24 Possible 
reasons for worse outcomes in elders include longer delays in seeking care, a higher burden of 
underlying CHD (often undiagnosed), more end-organ damage, and more comorbid conditions, 
all of which influence the effectiveness of treatment options.23 
 
Signs and symptoms of ACS 
 
Chest pain is the most common symptom of ACS. However, as individuals age, they are more 
likely to have atypical symptoms, such as dyspnea, diaphoresis, nausea and vomiting, unusual 
fatigue, and syncope.23 Thus, some elders may attribute atypical symptoms of ACS to other 
bodily conditions. Furthermore, elders are also more likely to have silent ischemia (no 
symptoms) with their ACS event compared with younger patients.23 Symptoms of NSTEMI ACS 
usually manifest in 1 of 3 ways: (1) as rest angina (angina at rest, usually longer than 
20 minutes), (2) new-onset angina (usually markedly limiting the person’s activities), or (3) as 
progressively increasing angina (increased frequency, increased duration, or a lower threshold of 
what precipitates symptoms) in patients with preexisting CHD.25 
 
Evaluation of ACS 
 
Initial evaluation of patients with known or suspected ischemia should include a focused history 
(current symptoms, CV risk factors, and past medical history) and physical examination (check 
HR, BP, heart rhythm, heart and lung sounds, peripheral pulses, and presence of peripheral 
edema). In addition, all patients with known or suspected ischemia should have a 12-lead ECG 
performed within 10 minutes of hospital presentation. While obtaining a 12-lead ECG, the 
patient should be given aspirin (160–325 mg, nonenteric coated), unless 
contraindicated.25 Aspirin should not be held while awaiting the 12-lead ECG. Unfortunately, 
many elderly patients, especially women or those with atypical symptoms, experience delay in 
receiving ECGs within the desired 10-minute time frame. In addition, elderly patients are more 
likely to have nondiagnostic ECGs or ECGs with abnormal baseline findings (eg, LVH, AF, 
bundle branch block, paced rhythms, or a prior MI), which confound the ability to detect acute 
ST-segment/T-wave changes.23 If the first ECG is nondiagnostic, yet the patient remains highly 
symptomatic, additional ECGs may be done every 15 to 30 minutes to detect possible ST-T-
wave changes.25 It is also important to obtain serial cardiac biomarkers (CK total, CK-MB, and 
troponin [the preferred biomarker]) to see if the patient has ruled in for an MI.25 However, 
troponin levels could be elevated for reasons other than ACS (eg, myocardial contusion, sepsis, 
pulmonary embolus, stroke, or advanced kidney disease).1,23 
 
Treatment of ACS 
 
Studies have shown that many elders experiencing an ACS event do not receive evidence-based 
treatment.23–25 As a result, in 2007 the American Heart Association (AHA) published a 2-part 
scientific statement on acute coronary care in the elderly, specifically addressing the care of 
elders suffering from NSTE ACS (Part I) and STEMI (Part II).24,25 In addition, the latest AHA 
guidelines for ACS and STEMI also include a special groups section for treating older adults.26,27 
 
All patients diagnosed with ACS who have continuing symptoms or hemodynamic instability 
should be admitted for at least 24 hours to the ICU.25 These patients should receive continuous 
ECG monitoring for detection of arrhythmias, frequent assessments of vital signs and mental 
status, and continuous ST-segment monitoring (if available) to detect recurrent ischemia.25 The 
most sensitive leads for viewing the infarct-related artery include Lead III for the right coronary 
artery, Lead V3 for the left anterior descending artery, and Lead V5 for the lateral and left 
circumflex artery. If the patient has ST-segment depression or elevation as the baseline, 
adjustments may be made to the ECG alarm settings to account for the baseline abnormalities. In 
addition, each patient should have access to defibrillation by the health care team if the patient 
experiences ventricular fibrillation.25 If the patient does not have major complications within the 
first 24 hours, he or she may be moved out of the ICU. Examples of major complications include 
sustained ventricular arrhythmias, sinus tachycardia, high-grade atrioventricular block, sustained 
hypotension, recurrent ischemia (documented by symptoms or ST-segment deviation), new 
mitral regurgitation, or HF, any of which would keep the patient in the ICU.25 
 
In addition, patients should receive supplemental oxygen by nasal cannula or facial mask if they 
have oxygen saturation less than 90%, are experiencing respiratory distress, or have other high-
risk features for respiratory compromise.25 Beyond continuous ECG monitoring and oxygen, 
treatment recommendations for elders with ACS are extrapolated from data with younger 
patients because most clinical trials have not included patients older than 75. In the ACS trials 
that have included elders, subgroup analysis has shown that in-hospital mortality decreases 
significantly as the number of recommended therapies given in the acute setting increases (eg, 
early use of aspirin, nitroglycerin, beta-blockers, ACE-inhibitors, heparin, glycoprotein IIb/IIIa 
inhibitors with percutaneous coronary intervention [PCI], and early cardiac catheterization 
[<48 hours]).23 In fact, adults 75 and older with positive troponin levels (eg, NSTE MI) have 
been shown to gain a greater absolute benefit with an early invasive strategy (cardiac 
catheterization within 48 hours) compared with younger adults, mainly because of the much 
worse outcomes for elders who are treated more conservatively.23 Table 7 lists the recommended 
pharmacologic agents for treating patients with NSTE MI and UA. 
 
TABLE 7 CAN BE FOUND AT THE END OF THE ARTICLE 
 
Treatment of STEMI should include urgent reperfusion therapy.23 Prompt reperfusion therapy 
(PCI within 90 minutes or fibrinolytic therapy within 30 minutes of hospital arrival) has shown a 
clear mortality benefit compared with not receiving reperfusion therapy, even for patients up to 
age 85.23,25 Selection of reperfusion therapy generally favors PCI (vs fibrinolytic 
therapy).23,25 However, the choice of reperfusion therapy also depends on risks and benefits for 
the individual patient, the time that symptoms began, and availability within the facility at the 
time of patient presentation.23,25 PCI is especially beneficial in elders with cardiogenic shock, 
prior stroke, large anterior infarcts, or those who present later in their symptom course 
(>6 hours).23 Benefits of urgent PCI include reduction in ischemic events and need for infarct-
related artery revascularization, improved 30-day survival, and lower risk of hemorrhagic stroke 
at 30 days.23 
 
Monitoring elders for bleeding 
 
Several of the therapies (eg, antiplatelet and antithrombin agents) used to treat ACS have an 
accompanied risk of bleeding. With elders, bleeding is a function of age, comorbid conditions 
(eg, impaired kidney function, anemia as a baseline, diabetes, low body weight, prior history of 
bleeding, alterations in hemostatic factors that help individuals clot) and concomitant medication 
use.23,27 Furthermore, bleeding is also related to excess dosing due to small body size and lower 
creatinine clearance.24,27 Kidney function should be determined by calculating the patient’s 
creatinine clearance, rather than using the serum creatinine. Nurses should also be diligent in 
monitoring elders for bleeding when these agents are given. Signs of bleeding may be more 
subtle and, if present, elders may downplay the symptoms. If a bleed is noted, the nurse should 
stop the offending agent (if known) and notify the medical team. 
 
Summary 
 
Nurses working in the ICU will frequently encounter elderly patients with CV conditions, either 
as the primary or secondary diagnosis. However, it is challenging to distinguish between 
pathology of disease and physiologic changes due to aging. Nurses need to assess patients 
carefully because signs and symptoms are more likely to be more subtle or atypical in elders as 
compared with younger patients. Nurses also should monitor elderly patients more closely to 
watch for side effects of medications, especially if underlying kidney or liver impairment exists. 
Finally, although elders may be at increased risk for side effects of therapy, studies have shown 
that patients in their advanced years have the most benefit to gain with use of guideline-directed 
medical therapy. 
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Table 1. Physiologic changes to the heart related to aging 
Physiologic Change Physiologic Mechanism Consequences 
Gradual loss of 
physiologic reserve 
• Physiologic stress (eg, blood loss, hypoxia, 
sepsis, volume depletion). 
• Vasoconstriction and sodium/water retention in 
the short term ↑ CO. 
• Vasoconstriction persists to ↑ afterload. 
Eventually heart fails to overcome ↑ afterload. 
• More vulnerable to disease. 
• LV volume ↑ over time → fluid in alveoli; pulmonary edema 
develops. 
• Maximum oxygen uptake ↓; hypoxemia occurs resulting in poor 
tissue/cellular perfusion. 
• CV function ↓. 
• Kidney function ↓. 
• Elasticity of skin and lungs ↓. 
Decreased response 
to sympathetic 
stimulation 
• Overall, declining receptor function and 
autonomic dysregulation. 
• Activity of SNS ↑ due to receptor dysfunction. 
• Activity of beta-receptor function ↓. 
• Baroreceptor reflex response ↓. 
• Orthostatic hypotension may result. 
• Less likely to ↑ HR to compensate for ↓ CO. 
• Need to ↑ preload or ventricular filling and stroke volume to 
compensate. 
• If hypovolemia exists, more likely to decompensate. 
Increased stiffness 
of heart and blood 
vessels 
• Arteriosclerotic process creates stiff arterial and 
ventricular walls. 
• Stiff ventricular walls become dependent on 
atrial contraction (atrial kick). 
• Atrial dilatation occurs as ventricles become 
stiff. 
• Atrial kick needed for diastolic filling. 
• Atrial kick lost if in atrial fibrillation (↓ diastolic filling time). 
• Increased resistance to ventricular ejection due to ↓ ventricular 
compliance. 
• Diastolic dysfunction results. 
Increased incidence 
of hypertension 
• Arterial distensibility ↓, especially large vessels. • More likely to have isolated systolic HTN. 
• Afterload ↑; more likely to develop LVH. 
• Progressive kidney dysfunction. 
Increased incidence 
of ischemic heart 
disease 
• Longer exposure to risk factors and becoming 
less active. 
• More likely to ↑ HR with physiologic stress to 
maintain CO; exacerbates ischemia. 
• Rate-related ischemia more common. 
• Symptoms may be atypical or absent. 
 
Increased incidence 
of heart failure 
• Progressive ↓ of cardiac myocytes. 
• Progressive ↑ in myocardial collagen. 
• Arterial distensibility ↓ resulting in ↓ CO. 
• CO less responsive to ↑ HR; have to ↑ preload 
to maintain (or ↑) CO. 
• Resting CO more likely to be maintained. 
• Acute illness ↑ dysfunction. 
• More likely to have impaired relaxation (diastolic dysfunction). 
• More dependent on preload. 
• Minor changes in fluid status may cause decompensation. 
Increased incidence 
of dysrhythmias 
• Autonomic tissue replaced by connective tissue 
and fat. 
• Fibrosis creates conduction abnormalities 
through intranodal tract and bundle of His. 
• May lead to sick sinus syndrome, atrial dysrhythmias, or bundle 
branch blocks. 
• Atrial dysrhythmias most common. 
• Sudden loss of atrial kick with atrial dysrhythmia may cause angina, 
HF, and/or ↓ BP. 
Abbreviations: BP, blood pressure; CO, cardiac output; CV, cardiovascular; HF, heart failure; HR, heart rate; HTN, hypertension; LV, left 
ventricular; LVH, left ventricular hypertrophy; SNS, sympathetic nervous system; ↑, increase; ↓, decrease. 
Data from Refs.1–4 
 
Table 2. Nursing care for hypertensive emergencies 
General BP goals: Lower MAP within 2–6 h of presentation, no more than 25% of the initial value at presentation. BP should be decreased ∼10% in 
the first hour, then ∼15%, gradually over 2–3 h. Exception: aortic dissection (see below). 
Consequences of 
HTN Emergency 
Signs and Symptoms Implications for Treatment 
Encephalopathy • Symptoms of cerebral edema or hypoperfusion: 
nausea/vomiting, headache, psychomotor agitation or 
slowing, visual changes, stupor, seizures, delirium, or 
papilledema. 
• Rare focal neurologic deficits include: paralysis, 
paresthesias, loss of muscle control/tone in a specific part of 
the body; voice, vision, or hearing loss. 
• Target BP: MAP lowered by maximum 20% or to DBP 
100–110 mm Hg within the first hour, then gradual reduction 
in BP to “normal” range over 48–72 h. 
• Medications of choice: intravenous sodium nitroprusside or 
labetalol. 
Ischemic stroke 
or intracerebral 
hemorrhage 
• Focal neurologic deficits (as above) suggest ischemic stroke 
or intracerebral hemorrhage. 
• Target BP for ischemic stroke: MAP lowered no more than 
15%–25%, DBP should not be <100–110 mm Hg in first 24 h. 
Some thrombolytic protocols may allow for more aggressive 
BP goals. 
• Target BP for ischemic stroke post-tPA: SBP <180 mm Hg 
or DBP <110 mm Hg. 
• Target BP for intracerebral hemorrhage: MAP lowered by 
20%–25%. 
Aortic dissection • Abrupt onset of ripping or tearing sensation in the chest, 
back, or both. 
• May mimic symptoms of acute myocardial ischemia, acute 
HF, stroke, musculoskeletal or pleuritic pain, or an acute 
abdomen. 
• Need to monitor for neurologic signs/symptoms of cerebral 
hypoperfusion, especially if BP is reduced too fast. 
• Target BP: SBP 120 mm Hg after 20 min, then maintain at 
100–120 mm Hg. 
• Medications of choice: combination of nitroprusside and 
beta-blocker (esmolol or labetalol). 
• Administer beta-blocker before nitroprusside because of the 
rapid onset of action to avoid reflex tachycardia that could 
worsen dissection. 
Acute coronary 
syndrome, 
including acute 
MI 
• Ischemic symptoms, such as pain or pressure in the jaw, 
neck, chest, arm, or back. Atypical symptoms may include 
dyspnea at rest or exertion, diaphoresis, and/or nausea. 
• Some elders have silent ischemia. 
• Target BP: MAP 60–100 mm Hg. 
• Medications of choice: nitrates (nitroglycerin) and beta-
blockers. 
• Avoid enalaprilat, nicardipine, or hyralazine (may induce 
reflex tachycardia and ↑ workload of heart). 
Consequences of 
HTN Emergency 
Signs and Symptoms Implications for Treatment 
LV failure • Acute pulmonary edema may be the cause or consequence 
of HTN crisis. 
• ↑ shortness of breath, hypoxia, pulmonary edema on 
examination or x-ray. 
• Target BP: MAP 60–100 mm Hg. 
• Medications of choice: sodium nitroprusside, nitroglycerin, 
IV enalaprilat, loop diuretics. Avoid labetalol, esmolol, and 
nicardipine in acute HF. 
Acute renal 
insufficiency 
• Proteinuria, elevated serum creatinine, hypokalemic 
metabolic alkalosis, and microangiopathic hemolytic anemia. 
• Level of kidney failure influenced by baseline kidney 
function. 
• Target BP: MAP lowered by 20%–25%. 
• Medication of choice: fenoldopam. 
• Avoid use of sodium nitroprusside in acute renal 
insufficiency. 
Postop HTN • Significantly elevated BP within 2 h after surgery. 
• Common causes: sympathetic activation and adrenergic 
surge postop, urinary retention, discontinuing anti-HTN 
agents preop. 
• Target BP: MAP lowered by 20%–25%. 
• Medication of choice: nicardipine, sodium nitroprusside, 
esmolol, or labetalol. 
• Caution: nicardipine may cause perioperative bleeding. 
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HF, heart failure; HTN, hypertension; IV, intravenous; LV, left ventricular; MAP, 
mean arterial pressure; Postop, postoperative; Preop, preoperative; SBP, systolic blood pressure; tPA, tissue plasminogen activator; ↑, increase. 
Data from Refs.7,8,10,11 
 
Table 3. Common medications used to treat hypertensive emergencies 
Medication/Indication Action Dosing Information Nursing Implications (in Addition to Monitoring for 
Hypotension) 
Sodium nitroprusside 
Most HTN 
emergencies, except 
acute HF. 
Vasodilator, arterial and 
venous. 
↓ preload and ↓↓ afterload. 
(No effect on cardiac output.) 
↓ pulmonary capillary wedge 
pressure and central venous 
pressure (by ↓ preload). 
↓ systemic vascular 
resistance (↓ afterload). 
0.25–10 μg/kg/min IV 
infusion; maximum dose 
for 10 min only. 
Onset of action: seconds to 
2 min. 
Duration: 1–3 min. 
Should start low and assess 
frequently. 
Side effects: nausea/vomiting/↑ ICP, may develop cyanide 
toxicity (especially in those with kidney or liver 
impairment), acidosis, coronary steal syndrome (can shunt 
blood from diseased vessels to well-perfused vessels). 
Watch for: cerebral hypoperfusion (due to ↑ ICP), ↓ 
coronary perfusion, and ototoxicity. 
Cautious use: elders and those with kidney impairment. 
May ↓ BP too rapidly. 
Nitroglycerin 
Most HTN 
emergencies, especially 
acute coronary 
ischemia or post-
CABG. 
Helpful if given in 
combination with 
Vasodilator (venous dilation 
with lower doses; arterial 
dilation too with higher 
doses). 
Smooth muscle vasodilation 
via nitric oxide. 
↓↓ preload and ↓ afterload. 
(No effect on cardiac output.) 
5–100 μg/min IV infusion. 
Onset of action: 2–5 min. 
Duration: 5–10 min. 
Titrate to desired response. 
Administer in glass containers and use special tubing. 
Side effects: headache, reflex tachycardia, vomiting, 
flushing. 
Tolerance may develop if administered continuously for 
24–48 h. 
Contraindications: cerebral hemorrhage (↑ ICP) and 
closed-angle glaucoma. 
Medication/Indication Action Dosing Information Nursing Implications (in Addition to Monitoring for 
Hypotension) 
diuretics, especially for 
acute pulmonary 
edema. 
Fenoldopam 
Most hypertensive 
emergencies, especially 
acute kidney 
impairment or acute 
HF. 
Vasodilator, arterial. 
Selective peripheral 
dopamine-receptor agonist. 
↑ perfusion to kidneys. 
↓ afterload; ↑ cardiac output; 
no effect on preload. 
0.1–0.6 μg/kg/min IV 
infusion; increments must 
not exceed 0.1 μg/kg/min 
at 20-min intervals. 
Maximum dose: 
1.7 μg/kg/min. 
Onset of action: 4–15 min. 
Duration: 30 min–4 h. 
May administer without intra-arterial BP monitoring. May 
withdraw without tapering. 
Side effects: headache (common), flushing, dizziness, 
reflex tachycardia or bradycardia, hypokalemia, ↑ 
intraocular pressure, local phlebitis. 
Contraindications: patients with glaucoma or ↑ intraocular 
pressure. 
Labetalol 
Most hypertensive 
emergencies, especially 
aortic dissection and 
pheochromocytoma 
crisis. 
Sympathetic blocker. 
Blocks alpha and beta-
receptors. 
↓ afterload; ↓ cardiac output; 
no effect on preload. 
20–80 mg IV bolus over 
2 min every 10 min (total 
dose 300 mg) or 0.5–
2 mg/min IV infusion. 
Onset of action: 5–10 min. 
Duration: 2–6 h. 
Side effects: bradycardia, heart block, worsened or new-
onset HF. 
Contraindications: symptomatic bradycardia or heart 
block; acute HF; reactive airway disease; cocaine toxicity. 
Esmolol 
Aortic dissection, 
perioperative HTN 
crises. Not for 
catecholamine excess. 
Sympathetic blocker. 
Ultrarapid, short-acting beta-
1 (cardioselective) blocker. 
↓ cardiac output; no effect on 
preload or afterload. 
80-mg bolus over 30 s, 
then 150 μg/kg/min IV 
infusion. 
Onset of action: 1–2 min. 
Duration: 10–20 min. 
Requires intra-arterial BP monitoring. 
Side effects: bradycardia, heart block, worsened or new-
onset HF; may cause thrombophlebitis and extravasation 
(including local necrosis). 
Contraindications: symptomatic bradycardia or heart 
block; acute HF; reactive airway disease; cocaine toxicity. 
Phentolamine 
Catecholamine excess. 
Sympathetic blocker. 
Nonselective alpha blocker. ↓ 
afterload; ↑ cardiac output. 
No effect on preload. 
5–15-mg IV bolus. 
Onset of action: 1–2 min. 
Duration: 10–15 min. 
Side effects: flushing, headache, reflex tachycardia. 
Nicardipine 
Most hypertensive 
emergencies, including 
perioperative and 
postoperative HTN. 
Calcium channel blocker, 3rd 
generation, dihydropyridine. 
Arterial vasodilator. No 
negative inotropic effects. 
↓ afterload; ↑ cardiac output; 
no effect on preload. 
Dose: 2–15 mg/h as IV 
infusion. 
Onset: 1–5 min. 
Duration: 15–120 min. 
Dose independent of body 
weight. Monitor and titrate 
to lowest dose. 
Side effects: reflex tachycardia. 
Cautious use: patients with CHD (tachycardia can ↑ 
ischemia) or those with suspected GI bleeding. 
Medication/Indication Action Dosing Information Nursing Implications (in Addition to Monitoring for 
Hypotension) 
Clevidipine 
Most hypertensive 
emergencies. 
Calcium channel blocker. 
Relaxes smooth muscles; ↓ 
peripheral resistance. 
↓ afterload; ↑ cardiac output; 
no effect on preload. 
1–2 mg/h doubling the 
dose at 90-s intervals 
initially; later at 5–10-min 
intervals based on BP 
effect. 
Titrate to maximum 
16 mg/h IV infusion. 
(Usual dose 4–6 mg/h). 
Onset of action: 1–4 min. 
Duration: 5–15 min. 
May administer in a central or peripheral IV line. 
Side effects: Nausea, vomiting, headache, AF. 
Contraindications: persons with AF; those who have soy 
allergy. 
Enalaprilat 
For HTN emergencies, 
especially acute HF. 
ACE inhibitor. 
↓ afterload; ↑ cardiac output; 
no effect on preload. 
1.25–5 mg (over 2–5 min) 
every 6 h IV bolus. 
Onset of action: 15–
30 min. 
Duration: 12–24 h. 
Side effects: headache, nausea, cough, hyperkalemia, 
worsened kidney function. 
Contraindication: History of ACE-inhibitor allergy or 
angioedema. 
Abbreviations: ACE, angiotensin-converting enzyme; AF, atrial fibrillation; BP, blood pressure; BUN, blood urea nitrogen; CABG, coronary artery 
bypass graft; CHD, coronary heart disease; GI, gastrointestinal; HF, heart failure; HTN, hypertension; ICP, intracranial pressure; IV, intravenous; ↑, 
increase; ↓, decrease; ⇊, more of a decrease. 
Data from Refs.7,10,11 
 
Table 4. Signs and symptoms of acute decompensated heart failure 
Body Symptom Sign/Symptoms of Pulmonary and Systemic Congestion Sign/Symptoms of Low Output (Inadequate Tissue 
Perfusion) 
General Weight gain (or stable weight if anorexia present at baseline); 
excessive thirst or dry mouth; may be apprehensive. 
Fatigue at rest, decreased exercise tolerance, weight loss, 
cachexia, temporary wasting, lethargy, and somnolence. 
Cardiovascular JVD, S3 gallop, new-onset or increased mitral regurgitation, 
right ventricular heave, increased central venous pressure or 
right atrial pressure. 
Absent JVD, decreased systolic BP (<85 mm Hg or if 
symptomatic), orthostatic BP and HR on standing, resting 
tachycardia, decreased mean arterial pressure, narrow pulse 
pressure, increased systemic vascular resistance, decreased 
temperature. 
Pulmonary Dyspnea on exertion, orthopnea, paroxysmal nocturnal 
dyspnea, nocturnal cough, rales, wheezes, pleural effusion, 
tachypnea, decreased oxygen saturations, pulmonary edema 
on chest x-ray. 
Dyspnea without orthopnea or paroxysmal nocturnal dyspnea, 
dyspnea on exertion with clearbreath sounds, clear chest x-
ray, decreased oxygen consumption, decreased arterial oxygen 
saturation. 
Body Symptom Sign/Symptoms of Pulmonary and Systemic Congestion Sign/Symptoms of Low Output (Inadequate Tissue 
Perfusion) 
Gastrointestinal Hepatomegaly, ascites, right upper quadrant tenderness, 
nausea, vomiting, diarrhea, anorexia, elevated liver function 
tests. 
Early satiety, anorexia, increased liver function 
tests without hepatomegaly, right upper quadrant tenderness, 
nausea, vomiting, bright red blood per rectum. 
Renal Urine output may be increased if oral intake is increased; 
increased nocturia. 
Increased blood BUN, increased Cr, oliguria or anuria; 
decreased serum sodium. 
Extremities Warm pitting peripheral edema, strong peripheral pulses. Cool; absent, or nonpitting edema; weak peripheral pulses. 
Abbreviations: BP, blood pressure; BUN, blood urea nitrogen; Cr, creatinine; JVD, jugular vein distension. 
Data from Refs.12,14–16 
 
Table 5. Classification clinical profiles and treatment of acute decompensated heart failure 
Profile Characteristics Treatment 
Cold and wet Inadequate tissue perfusion 
Congested 
IV loop diuretic (not as effective if kidney perfusion is compromised) 
Inotropes (dopamine, dobutamine, or milrinone) 
Warm and wet Adequate tissue perfusion 
Congested 
IV loop diuretic 
Vasodilators (nitroglycerin, sodium nitroprusside, or nesiritide) 
Cold and dry: least common profile Inadequate tissue perfusion 
Not congested 
Inotropes (as above) 
Avoid use of diuretics and vasodilators due to profound hypotension or 
irreversible organ damage 
Warm and dry: the target 
profile after treatment 
Adequate tissue perfusion 
Not congested 
Search for other causes of HF. 
Avoid IV diuretics to prevent hypotension 
Abbreviations: HF, heart failure; IV, intravenous. 
Data from Refs.12,14–16 
 
Table 6. Intravenous medications used to treat acute decompensated heart failure 
Medication 
Class/Action(s) 
Examples/Dose Recommendations Side Effects Nursing Implications 
Loop diuretics 
↑ urinary excretion of 
sodium, chloride, and 
water. 
↓ circulating 
intravascular volume (↓ 
preload and central 
venous pressure). 
↓ signs of fluid 
retention. 
Furosemide 
Loading IV dose: 40 mg. 
Continuous IV infusion should be adjusted to CrCl; 
typically 10–40 mg/h. 
IV doses exceeding 300 mg/d in patients with 
ADHF have increased mortality. 
Bumetanide 
Loading IV dose: 1 mg. 
Maximum IV dose: 10 mg/d. 
Most serious: If given too 
rapidly may cause 
symptomatic hypotension, 
worsened kidney function, 
serious serum electrolyte 
abnormalities. 
Most common: Worsened 
kidney function (↑ serum 
BUN, creatinine). 
Fluid volume deficit 
Monitor BP, HR, and cardiac 
rhythm every 1–2 h. 
Monitor signs and symptoms of 
congestion and changes in body 
weight. 
Daily weights, comparing to 
patient’s dry weight (weight before 
decompensation). 
Monitor intake and output records. 
Monitor serum electrolytes. Report 
Medication 
Class/Action(s) 
Examples/Dose Recommendations Side Effects Nursing Implications 
Continuous IV infusion should be adjusted to CrCl; 
typically 0.5–2 mg/h. 
Torsemide 
Loading IV dose: 20 mg. 
Continuous IV infusion: typically 5–20 mg/h. 
(hypovolemia, 
dehydration, orthostatic 
hypotension, dizziness, 
presyncope, syncope). 
Electrolyte imbalances (↓ 
potassium, sodium, 
calcium; metabolic 
alkalosis; ↑ glucose, lipid 
levels, uric acid). 
Less common: ototoxicity. 
abnormal values to the medical team 
caring for the patient. 
Instruct patient to change positions 
slowly to avoid syncope. 
Monitor for ringing in the ears or 
hearing loss. 
Vasodilators 
↓ BP (↓ preload and 
afterload by venous 
and arterial 
vasodilation). 
↓ PCWP and CVP (by 
↓ preload). 
↓ SVR (afterload). 
All need to be 
administered by an IV 
infusion pump. Patients 
with a peripheral IV are 
at risk for infiltration 
and necrosis. 
Monitor BP, HR, and 
cardiac rhythm every 
1–2 h. 
Need to wean 
vasodilators slowly to 
avoid rebound 
vasoconstriction. 
Nitroglycerin 
Initial dose: 10–20 μg/min. 
Typical dose range: 5–200 μg/min. 
Adjustment increment: 10–20 μg/min every 5–
15 min. 
Maximum dose: titrate up to a max of 200 μg/min. 
Symptomatic hypotension 
(esp. if given with IV 
diuretic), headache, 
abdominal discomfort, 
reflex tachycardia, 
paradoxic bradycardia. 
May develop tolerance (decreased 
response to drug) if receiving a 
continuous infusion >24 h. 
Sodium nitroprusside 
Initial dose: 0.2–0.3 μg/kg/min. 
Typical dose range: 0.5–5 μg/kg/min (usually 5–300 
μg/min). 
Adjustment increment: 0.25–0.50 μg/kg/min every 
5–15 min (while maintaining an SBP of >90 mm Hg 
or MAP >65 mm Hg). 
Maximum dose: 5 μg/kg/min. 
May cause profound 
hypotension. 
Serious side effects: 
cyanide and thiocyanate 
toxicities especially in 
patients with liver or 
kidney impairment. 
 
Need to monitor patients for cyanide 
toxicity (change in mental status, 
muscle spasms, convulsions, 
hemodynamic instability, 
unexplained metabolic or lactic 
acidosis). Risk of toxicity ↓ if given 
at lower doses and used for <72 h. 
Nesiritide 
Initial loading (bolus) dose: 2 μg/kg. (May omit 
loading dose if there is concern for hypotension.) 
Followed by infusion of: 0.1 μg/kg/min. 
Adjustment increment: 0.005 μg/kg/min; bolus 
1 μg/kg/min every 3 h to maximum dose. 
Maximum dose: 0.03 μg/kg/min. 
Symptomatic hypotension 
(especially if given with 
IV diuretic), headache, 
worsening kidney 
function (dose dependent). 
Serious side effect: May 
worsen ischemia in 
patients with ACS. 
Should not be given to patients with 
acute cardiac ischemia (patients with 
ACS). 
Medication 
Class/Action(s) 
Examples/Dose Recommendations Side Effects Nursing Implications 
Inotropes 
Dopamine 
Sympathomimetic (↑ 
HR and CO). Effects 
are dose dependent. 
Best choice for “cold 
and dry” or those in 
cardiogenic shock. 
 
Starting dose: 2 μg/kg/min (no loading dose). 
Adjustment increment: 0.005 μg/kg/min; bolus 
1 μg/kg every 3 h to maximum dose of 
10 μg/kg/min. 
Note: Low dose (<3 μg/kg/min) = ↑ urine output and 
sodium excretion. Moderate dose (3–5 μg/kg/min) = 
inotrope effect (↑ CO and SBP). High dose 
(>5 μg/kg/min) = vasopressor effect (↑ CO, BP; ↓ 
blood to kidneys and periphery). 
 
Common side effect: 
Tachycardia, headache, 
nausea, ↓ urine output 
(with high doses). 
Serious side effect: tissue 
necrosis. 
 
All should be given via an infusion 
pump. All should be started and 
stopped gradually (weaned). 
Frequent monitoring of BP, HR, and 
cardiac rhythm. 
Notify medical team if patient 
develops symptomatic hypotension 
or serious arrhythmia. 
Most (not all) complications are 
related to higher doses and/or longer 
lengths of time on IV inotropes. 
Dobutamine 
Synthetic 
catecholamine. 
Stimulates β1 and β2 
adrenergic receptors (↑ 
HR, BP, and 
contractility). Dose 
dependent ↑ CO and ↓ 
PCWP. 
Starting dose: 2–5 μg/kg/min (*no loading dose). 
Typical dose range: 2.5–20 μg/kg/min (side effects 
are dose dependent). 
Adjustment increment: 2.5–5 μg/kg/min every 5–
15 min. 
Common side effect: ↑ or 
↓ BP, headache, 
tachycardia (more likely 
with this inotrope), 
nausea, fever. 
Serious side effect: 
hypersensitivity, increased 
myocardial ischemia, AF. 
Best choice for patients who are 
“cold and dry” (SBP <90 mm Hg). 
Avoid in patients with ACS (due to 
↑ HR and myocardial oxygen 
demand). 
Milrinone 
Phodiesterase type-3 
inhibitor. ↑ intracellular 
calcium concentration, 
myocardial 
contractility and 
myocardial relaxation. 
(↑ arterial and venous 
vasodilation, ↓ SVR 
and PVR, ↑ CO). 
Initial loading dose: 50 μg/kg (may omit if a concern 
for hypotension). 
Starting infusion: 0.25 μg/kg/min. 
Typical dose range: 0.25–0.75 μg/kg/min. 
Adjustment increment: titration based on 
hemodynamic response (↑ CO and ↓ PCWP). 
Common side effects: 
Tachycardia, hypotension 
(more likely with this 
inotrope), atrial and 
ventricular arrhythmias. 
Serious side effects: 
Long-term use associated 
with decreased survival 
(cardiac arrest). 
Best choice for patients who are 
“cold and wet” (SBP <90 mm Hg). 
Better choice for patients who are on 
beta-blockers (compared to 
dobutamine which stimulates beta-
receptors). 
Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; BP, blood pressure; CO, cardiac output; CrCl, creatinine clearance; CVP, 
central venous pressure; HR, heart rate; IV, intravenous; PCWP, pulmonary capillary wedge pressure; PVR, peripheral vascular resistance; SBP, 
systolic blood pressure; SVR, systemic vascular resistance; ↑, increase; ↓, decrease. 
Data from Refs.12,14–16,19 
 
Table 7. Pharmacologic treatment for patients with ACS 
Medication/Use 
in ACS 
Indication Nursing Implications 
NTG 
Anti-ischemic 
therapy. 
Sublingual NTG 0.4 mg every 5 min up to 3 doses to treat 
ongoing ischemic discomfort. 
If symptoms continue after 3 sublingual NTGs, then assess 
the need for IV nitroglycerin. 
Intravenous NTG to treat persistent ischemia, pulmonary 
congestion, or HTN associated with the first 48 h of the ACS 
event. 
Monitor for BP/HR for hypotension and tachycardia. 
Caution the patient that he or she may experience a headache. 
Treat headache with prn pain medications. 
Tolerance may develop in patients who have received >24 h of 
continuous IV NTG. For those who require IV NTG beyond 
24 h, an increase of dose may be needed to maintain the anti-
ischemic effect. Patients who have been symptom free for 12–
24 h after IV NTG may be converted to oral or topical NTG. 
Contraindications: SBP <90 mm Hg or BP ≥30 mm Hg lower 
than their baseline, severe bradycardia (HR <50/min), 
tachycardia (HR>100/min) in the absence of symptomatic HF 
or RV infarct. 
Should not be given in patients who have received a 
phosphodiesterase inhibitor for erectile dysfunction within 24 h 
of sildenafil or 48 h of tadalafil use. The time frame for 
vardenafil has not been established. 
Beta-blocker 
therapy 
Anti-ischemic, 
anti-arrhythmic, 
mortality 
reduction. 
Oral beta-blocker therapy should be given within the first 
24 h of an ACS event. 
IV beta-blockers may be considered for ongoing ischemic 
symptoms, especially with concurrent tachycardia or HTN. 
Nondihydropyridine calcium channel blockers (verapamil or 
diltiazem) may be given if beta-blockers are not tolerated or 
are contraindicated (except if severe LV dysfunction or other 
contraindications). 
Monitor the patient’s HR, BP, and heart rhythm. 
Lower doses may be needed initially for elders to evaluate the 
patient’s response (due to the high first-pass effect in the liver 
and due to age-related changes to baroreceptors and beta-
adrenergic receptors in the body). 
Contraindications: signs of HF, evidence of low output state 
(marked hypotension), symptomatic bradycardia, advanced 
heart block (2nd-degree or 3rd-degree AV block), active asthma 
or reactive airway disease. 
ACE inhibitor 
therapy 
↓ ventricular 
remodeling. ↑ 
long-term 
survival. 
Oral ACE inhibitor within first 24 h if the patient has 
pulmonary congestion, LVEF ≤40%. 
Substitute: ARB. 
Monitor the patient’s HR, BP, and heart rhythm. 
Watch for hyperkalemia or a decline in kidney function in 
elders, especially those with underlying kidney impairment. 
Contraindications: SBP <100 mg Hg or BP ≥30 mm Hg below 
their baseline. 
Medication/Use 
in ACS 
Indication Nursing Implications 
Antiplatelet 
therapy (aspirin, 
clopidogrel, 
prasugrel, or 
tigarelor). 
Aspirin 160–325 mg, nonenteric coated should be chewed at 
the time of presentation and given orally daily thereafter 
(100–325 mg). 
Substitute: clopidogrel 75 mg daily (if aspirin allergy). 
Dual antiplatelet therapy (aspirin + clopidogrel, prasugrel, or 
tigarelor) should be considered for those having an early 
invasive approach (cardiac catheterization within 48 h). 
Monitor patients for bleeding. 
When using dual antiplatelet therapy, aspirin doses should be 
≤100 mg daily due to the increased risk of bleeding. 
Prasugrel is contraindicated in patients ≥75 y due to ↑ risk of 
death and intracranial bleeding. 
Intravenous 
glycoprotein 
IIb/IIIa 
inhibitors 
Eptifibatide: Weight-based bolus of 180 μg/kg and infusion 
of 2.0 μg/kg/min. Infusion should be adjusted if CrCl 
<50 mL/min to 1.0 μg/kg/min. 
Tirofiban: Weight-based bolus of 12 μg/kg and infusion of 
0.1 μg/kg/min. Should be adjusted for kidney function (CrCl 
<30 mL/min) to bolus of 6 μg/kg and infusion of 
0.05 μg/kg/min. 
Calculate the patient’s CrCl each day to verify that the patient is 
on the proper dose. 
Monitor the patient for bleeding. 
Increased bleeding is seen with elderly patients, especially if not 
properly weight adjusted or dose adjusted based on CrCl. 
Bleeding risk also increases with the number of antithrombin 
and antiplatelet agents given concurrently. 
Antithrombin 
therapy 
(heparin) 
Unfractionated heparin: weight-based bolus of 60 μg/kg and 
infusion of 12 μg/kg/min. Maximum bolus 4000 units and 
infusion of 900 u/h or 5000-unit bolus and infusion of 1000 
u/h if patient weighs >100 kg. 
LMWH: weight-based dose of 1 mg/kg every 12 h. 
Adjustment in infusion for kidney function. If CrCl 
<30 mL/min, then 1 mg/kg subcutaneously every 24 h. 
Monitor the patient for bleeding. Every elderly patient should 
have CrCl calculated every day. 
Patients are at ↑ risk for bleeding if altered kidney function. 
Alterations in body composition and protein levels in elders 
may result in overestimation of heparin dosing. 
Abbreviations: ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; AV, atrioventricular; BP, 
blood pressure; CO, cardiac output; CrCl, creatinine clearance; CVP, central venous pressure; HR, heart rate; IV, intravenous; LMWH, low 
molecular weight heparin; LVEF, left ventricular ejection fraction; NTG, nitroglycerin; prn, as needed; RV, right ventricular; SBP, systolic blood 
pressure; u/h, units per hour; ↑, increase; ↓, decrease. 
Data from Refs.24–26 
 
